Glaukos

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Glaukos reports robust Q4 earnings, sets ambitious growth plans for 2023

Glaukos delivered strong financial performance in Q4 2022 and outlined ambitious plans for 2023, focusing on innovation and market expansion. Despite staffing challenges and operating expense growth, the company remains optimistic about its growth prospects. Opportunities in advancing key products and addressing market dynamics position Glaukos for continued success.

Glaukos reports strong Q1 earnings, eyes international market opportunities

Glaukos delivered robust financial results in Q1 2023, showcasing growth in key franchises and advancing its pipeline. The company faces challenges in operational efficiency and market expansion but holds opportunities in international markets and innovative product offerings. Overall, Glaukos remains well-positioned for future growth and success.

Glaukos reports record Q2 sales, eyes international growth opportunities

Glaukos delivered strong Q2 results, with a focus on strategic investments for iDose launch and maintaining growth momentum. Challenges include reimbursement changes and healthcare trend normalization. Opportunities lie in international expansion and new product launches.

Glaukos reports robust Q3 sales, eyes early glaucoma intervention

Glaukos shows strong performance with sales growth and strategic developments.
Facing challenges in market share and FDA concerns but seizing growth opportunities.
Confidence in ongoing projects and commitment to advancing glaucoma therapies.
Strategic focus on innovation and market expansion in the glaucoma sector.

Glaukos achieves record sales, focuses on innovation and market growth

Glaukos delivered strong financial performance, with a focus on innovation and market leadership in the ophthalmic space.
The company's strategic strengths lie in its product portfolio, market access initiatives, and commitment to driving change in the standard of care.
Challenges include managing physician time allocation, balancing growth strategies, and ensuring successful product launches.
Opportunities for Glaukos include increased adoption of innovative products, pipeline advancements, and continued investment in driving future growth.

Glaukos reports record sales and raises guidance for 2024

Glaukos is on track for strong financial performance with record sales and increased guidance. The company faces challenges with iDose adoption and reimbursement timelines but sees opportunities for growth in various product lines.

Glaukos reports record Q2 sales, raises guidance amid innovation focus

Glaukos delivered strong financial performance in Q2 2024, with record net sales and raised full year guidance, driven by robust sales across key franchises.
The company's focus on innovation, balance sheet strengthening, and market expansion positions it well for future growth and competitive advantage.
While facing regulatory and operational challenges, Glaukos has opportunities to capitalize on market trends, product adoption, and international expansion.
Navigating these challenges and leveraging opportunities will be crucial for Glaukos to sustain growth momentum and enhance shareholder value.

Glaukos reports record Q3 sales, eyes growth through product launches

Glaukos delivered strong financial performance in Q3 2024, with record net sales and raised full year guidance. The company's focus on product innovation, market expansion, and reimbursement strategies positions it well for future growth. While challenges in financial restructuring and market access exist, opportunities in product launches and international expansion offer promising prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Globus Medical

PROCEPT BioRobotics Corp

Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.

3 Medtech Stocks Likely to Top Estimates This Earnings Season

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 2.

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.

Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023. Preliminary and unaudited total net sales for the fourth quarter and full year of 2023 are expected to be in excess of $81 million and $313 million, respe.

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA. A live and archived webcast for these events, where applicable, will be available in.

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.

Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?

Glaukos shares rose more than 7% in Thursday premarket trading after the company announced US Food and Drug Administration (FDA) approval for iDose TR (travoprost intracameral implant). The iDose TR is a micro-invasive intraocular implant designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Glaukos shares jump on FDA approval of iDose TR eye implant

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for a single administration per eye of iDose® TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (IO.

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Why Is Glaukos (GKOS) Down 0.4% Since Last Earnings Report?

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 10:55 a.m. ET in New York City. A live and archived webcast for these events, where applicable, will be available in the Investors sect.

Glaukos Announces Participation in Stifel Healthcare Conference

Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

Glaukos Corporation (NYSE:GKOS ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations & Corporate Affairs Tom Burns - Chairman & Chief Executive Officer Joe Gilliam - President & Chief Operating Officer Alex Thurman - Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Joanne Wuensch - Citigroup David Saxon - Needham Allen Gong - JPMorgan Anthony Petrone - Mizuho Group George Sellers - Stephens Operator Hello, and welcome to Glaukos Corporation's Third Quarter 2023 Financial Results Conference Call. Copies of the company's press release and quarterly summary document both issued after the market closed today are available at www.glaukos.com.

Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key highlights include: Net sales of $78.0 million in Q3 2023 increased 10% year-over-year on a reported basis and 9% year-over-year on a constant currency basis. Glaucoma net sales of $5.

Glaukos Announces Third Quarter 2023 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 3-6, 2023 in San Francisco, CA. Glaukos will be exhibiting onsite at booth #1630. Key Glaucoma Pr.

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2023 financial results after the market close on Wednesday, November 1, 2023. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 1, 2023. A link t.

Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 12:45 p.m. ET in Boston, MA. A live and archived webcast for this event will be available in the Investors section of the Glauko.

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics

Glaukos Corporation (NYSE:GKOS ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Christopher Lewis - VP, IR & Corporate Affairs Thomas Burns - Chairman & CEO Joseph Gilliam - President & COO Alex Thurman - SVP & CFO Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company Ryan Zimmerman - BTIG Charles Ellson - Wells Fargo Securities Joseph Conway - Needham & Company Joanne Wuensch - Citigroup George Sellers - Stephens Inc. Phillip Dantoin - Piper Sandler & Co. Anthony Petrone - Mizuho Securities Allen Gong - JPMorgan Chase & Co. Operator Welcome to Glaukos Corporation's Second Quarter 2023 Financial Results Conference Call. Copies of the company's press release and quarterly summary document both issued after the market closed today are available at www.glaukos.com.

Glaukos Corporation (GKOS) Q2 2023 Earnings Call Transcript

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2023. Key highlights include: Net sales of $80.4 million in Q2 2023 increased 11% year-over-year. Glaucoma net sales of $61.9 million in Q2 2023 increased 10% year-over-year. Corneal Health net sal.

Glaukos Announces Second Quarter 2023 Financial Results

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detection of eye diseases more efficient.

Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a collaboration and marketing agreement with Radius XR, Inc., whereby Glaukos will become the exclusive sales agent to market, promote and solicit orders for the Radius XR™ wearable patient engagement and diagnostic system withi.

Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.

Aehr Test Systems

Some markets gave up their early gains on Friday but still were higher for the week. Aehr Test Systems expects a strong year in fiscal 2024.

News for Glaukos Stock (GKOS)